

# M G Kirby

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4995344/publications.pdf>

Version: 2024-02-01

55  
papers

2,312  
citations

304368

22  
h-index

214527

47  
g-index

58  
all docs

58  
docs citations

58  
times ranked

3303  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterising the castration-resistant prostate cancer population: a systematic review. <i>International Journal of Clinical Practice</i> , 2011, 65, 1180-1192.	0.8	614
2	Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. <i>International Journal of Clinical Practice</i> , 2010, 64, 848-857.	0.8	197
3	The temporal relationship between erectile dysfunction and cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2007, 61, 2019-2025.	0.8	118
4	Endothelial dysfunction links erectile dysfunction to heart disease. <i>International Journal of Clinical Practice</i> , 2005, 59, 225-229.	0.8	113
5	Is erectile dysfunction a marker for cardiovascular disease?. <i>International Journal of Clinical Practice</i> , 2001, 55, 614-8.	0.8	97
6	British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice. <i>Journal of Sexual Medicine</i> , 2017, 14, 1504-1523.	0.3	94
7	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Menâ€”2017. <i>Journal of Sexual Medicine</i> , 2018, 15, 430-457.	0.3	91
8	Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. <i>International Journal of Clinical Practice</i> , 2007, 61, 1349-1355.	0.8	76
9	A practical approach to the management of nocturia. <i>International Journal of Clinical Practice</i> , 2017, 71, e13027.	0.8	76
10	Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. <i>International Journal of Clinical Practice</i> , 2015, 69, 199-217.	0.8	75
11	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. <i>Heart</i> , 2016, 102, 1750-1756.	1.2	74
12	Erectile Dysfunction: Monitoring Response to Treatment in Clinical Practiceâ€”Recommendations of an International Study Panel. <i>Journal of Sexual Medicine</i> , 2007, 4, 448-464.	0.3	71
13	Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of coâ€”diagnosis. <i>International Journal of Clinical Practice</i> , 2013, 67, 606-618.	0.8	63
14	Overactive bladder: Is there a link to the metabolic syndrome in men?. <i>Neurourology and Urodynamics</i> , 2010, 29, 1360-1364.	0.8	56
15	Original Researchâ€”ED Pharmacotherapy: Characteristics, Behaviors, and Attitudes of Men Bypassing the Healthcare System When Obtaining Phosphodiesterase Type 5 Inhibitors. <i>Journal of Sexual Medicine</i> , 2010, 7, 1237-1246.	0.3	49
16	Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. <i>International Journal of Clinical Practice</i> , 2015, 69, 106-123.	0.8	49
17	Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. <i>International Journal of Clinical Practice</i> , 2011, 65, 1005-1013.	0.8	48
18	Testosterone and the Heart. <i>European Cardiology Review</i> , 2019, 14, 103-110.	0.7	39

#	ARTICLE	IF	CITATIONS
19	Epidemiology of castration resistant prostate cancer: A longitudinal analysis using a UK primary care database. <i>Cancer Epidemiology</i> , 2012, 36, e349-e353.	0.8	37
20	Development of <sc>UK</sc> recommendations on treatment for postâ€surgical erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2014, 68, 590-608.	0.8	32
21	Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice. <i>BJU International</i> , 2012, 110, 710-718.	1.3	29
22	Can simvastatin improve erectile function and healthâ€related quality of life in men aged â‰¥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ <sc&gt;isrctn&lt; <i="" sc&gt;66772971].="">BJU International, 2013, 111, 324-333.</sc&gt;isrctn&lt;>	1.3	26
23	The Circle of Lifestyle and Erectile Dysfunction. <i>Sexual Medicine Reviews</i> , 2015, 3, 169-182.	1.5	19
24	Prostate-specific antigen testing rates and referral patterns from general practice data in England. <i>International Journal of Clinical Practice</i> , 2016, 70, 312-318.	0.8	18
25	Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study. <i>International Journal of Clinical Practice</i> , 2011, 65, 797-806.	0.8	16
26	Management of erectile dysfunction after prostate cancer treatment: cross-sectional surveys of the perceptions and experiences of patients and healthcare professionals in the UK. <i>BMJ Open</i> , 2019, 9, e030856.	0.8	16
27	Managing stress urinary incontinence - a primary care issue. <i>International Journal of Clinical Practice</i> , 2006, 60, 184-189.	0.8	13
28	Impact on clinical practice of the Joint British Societiesâ€™ cardiovascular risk assessment tools. <i>International Journal of Clinical Practice</i> , 2009, 63, 1683-1692.	0.8	13
29	Integrative review on the nonâ€invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. <i>International Journal of Clinical Practice</i> , 2015, 69, 1184-1208.	0.8	12
30	Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial. <i>BMC Urology</i> , 2014, 14, 24.	0.6	10
31	Erectile dysfunction and testosterone deficiency as cardiovascular risk factors?. <i>International Journal of Clinical Practice</i> , 2018, 72, e13054.	0.8	9
32	UK policy statements on testosterone deficiency. <i>International Journal of Clinical Practice</i> , 2017, 71, e12901.	0.8	8
33	Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2013, 67, 1034-1039.	0.8	7
34	GPs views and understanding of PSA testing, screening and early detection; survey. <i>International Journal of Clinical Practice</i> , 2016, 70, 389-395.	0.8	6
35	Development of a conceptual framework to improve sexual wellbeing communication in routine prostate cancer care. <i>Patient Education and Counseling</i> , 2020, 103, 1150-1160.	1.0	6
36	The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 591-599.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Prescription switching: Rationales and risks. International Journal of Clinical Practice, 2020, 74, e13429.	0.8	4
38	The management of sexual dysfunction resulting from radiotherapy and androgen deprivation therapy to treat prostate cancer: A comparison of uroâ€œoncology practice according to disease stage. International Journal of Clinical Practice, 2021, 75, e13873.	0.8	4
39	Effects of a Brief E-Learning Resource on Sexual Attitudes and Beliefs of Healthcare Professionals Working in Prostate Cancer Care: A Pilot Study. International Journal of Environmental Research and Public Health, 2021, 18, 10045.	1.2	4
40	Efficacy, Use, and Acceptability of a Web-Based Self-management Intervention Designed to Maximize Sexual Well-being in Men Living With Prostate Cancer: Single-Arm Experimental Study. Journal of Medical Internet Research, 2021, 23, e21502.	2.1	3
41	The Tablet-Based, Engagement, Assessment, Support, and Sign-Posting (EASSi) Tool for Facilitating and Structuring Sexual Well-Being Conversations in Routine Prostate Cancer Care: Mixed-Methods Study. JMIR Cancer, 2020, 6, e20137.	0.9	3
42	Applying the evidence: guidelines in primary care. British Heart Journal, 2004, 90, iv6-iv8.	2.2	2
43	A new look at the hormonal and metabolic changes in the ageing male. International Journal of Clinical Practice, 2008, 62, 672-674.	0.8	2
44	Is duloxetine safe and effective for the treatment of overactive bladder?. Nature Reviews Urology, 2008, 5, 188-189.	1.4	2
45	The importance of knowing testosterone levels in patients with prostate cancer. BJU International, 2014, 114, 164-165.	1.3	2
46	ACHIEVING EFFECTIVE RISKâ€œFACTOR MODIFICATION IN UROLOGICAL PATIENTS. BJU International, 2008, 101, 793-794.	1.3	1
47	The counterfeit conundrum. International Journal of Clinical Practice, 2012, 66, 229-231.	0.8	1
48	Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study. International Journal of Clinical Practice, 2015, 69, 853-862.	0.8	1
49	PDE-5 inhibitors: spoilt for choice. International Journal of Clinical Practice, 2006, 60, 893-894.	0.8	0
50	Helping the failing heart and penis. International Journal of Clinical Practice, 2007, 61, 716-718.	0.8	0
51	Cardiovascular risk estimation - What is missing?. International Journal of Clinical Practice, 2011, 65, 111-113.	0.8	0
52	Testosterone measurement - mandatory in ALL men with ED - a response. International Journal of Clinical Practice, 2012, 66, 113-114.	0.8	0
53	Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU International, 2013, 111, 854-856.	1.3	0
54	New testosterone 2% gel using Ferring Advanced Skin Technology (FAST), for the treatment of testosterone deficiency in men, with a novel applicator. Expert Review of Endocrinology and Metabolism, 2020, 15, 217-226.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Influences and Complications. , 2020, , 217-266.		0